Skip to main content

Flucytosine Disease Interactions

There are 4 disease interactions with flucytosine.

Major

Flucytosine (applies to flucytosine) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Immunodeficiency

Flucytosine may frequently cause bone marrow toxicity, which can be irreversible and fatal in immunosuppressed patients. Flucytosine should be used with extreme caution in patients with preexisting bone marrow suppression. Frequent blood counts are recommended.

References

  1. Record CO, Skinner JM, Sleight P, Speller DC "Candida endocarditis treated with 5-fluorocytosine." Br Med J 01/30/71 (1971): 262-4
  2. Harder EJ, Hermans PE "Treatment of fungal infections with flucytosine." Arch Intern Med 135 (1975): 231-7
  3. Wise GJ, Goldberg P, Kozinn PJ, Nawabi IU "Agranulocytosis associated with flucytosine for urinary candidiasis." Urology 8 (1976): 490-1
  4. Kauffman CA, Frame PT "Bone marrow toxicity associated with 5-fluorocytosine therapy." Antimicrob Agents Chemother 11 (1977): 244-7
  5. Bennett JE, Dismukes WE, Duma RJ, et al. "A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis." N Engl J Med 301 (1979): 126-31
  6. Stamm AM, Diasio RB, Dismukes WE, et al. "Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis." Am J Med 83 (1987): 236-42
  7. "Product Information. Ancobon (flucytosine)." Roche Laboratories PROD (2002):
View all 7 references
Major

Flucytosine (applies to flucytosine) renal dysfunction

Major Potential Hazard, High plausibility.

Flucytosine must be given with extreme caution to patients with impaired renal function. Flucytosine is excreted primarily by the kidneys, and renal impairment may lead to accumulation of the drug. Serum concentrations of the drug should be monitored to determine the adequacy of renal excretion in such patients. Dosage adjustments should be made in patients with renal insufficiency to prevent progressive accumulation of active drug. Close monitoring of renal, hematologic and hepatic function in all patients is recommended.

References

  1. Wade DN, Sudlow G "The kinetics of 5-fluorocytosine elimination in man." Aust N Z J Med 2 (1972): 153-8
  2. Drouhet E, Babinet P, Chapusot JP, Kleinknecht D "5-fluorocytosine in the treatment of candidiasis with acute renal insufficiency." Biomedicine 19 (1973): 408-14
  3. Dawborn JK, Page MD, Schiavone DJ "Use of 5-fluorocytosine in patients with impaired renal function." Br Med J 11/17/73 (1973): 382-4
  4. Schonebeck J, Polak A, Fernex M, Scholer HJ "Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function." Int J Exp Clin Chemother 18 (1973): 321-36
  5. Cutler RE, Blair AD, Kelly MR "Flucytosine kinetics in subjects with normal and impaired renal function." Clin Pharmacol Ther 24 (1978): 333-42
  6. "Product Information. Ancobon (flucytosine)." Roche Laboratories PROD (2002):
  7. Lau AH, Kronfol NO "Elimination of flucytosine by continuous hemofiltration." Am J Nephrol 15 (1995): 327-31
View all 7 references
Moderate

Flucytosine (applies to flucytosine) hemodialysis

Moderate Potential Hazard, High plausibility.

Flucytosine is substantially removed by hemodialysis and should be administered after dialysis.

References

  1. Drouhet E, Babinet P, Chapusot JP, Kleinknecht D "5-fluorocytosine in the treatment of candidiasis with acute renal insufficiency." Biomedicine 19 (1973): 408-14
  2. Dawborn JK, Page MD, Schiavone DJ "Use of 5-fluorocytosine in patients with impaired renal function." Br Med J 11/17/73 (1973): 382-4
  3. Schonebeck J, Polak A, Fernex M, Scholer HJ "Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function." Int J Exp Clin Chemother 18 (1973): 321-36
  4. Cutler RE, Blair AD, Kelly MR "Flucytosine kinetics in subjects with normal and impaired renal function." Clin Pharmacol Ther 24 (1978): 333-42
  5. "Product Information. Ancobon (flucytosine)." Roche Laboratories PROD (2002):
  6. Lau AH, Kronfol NO "Elimination of flucytosine by continuous hemofiltration." Am J Nephrol 15 (1995): 327-31
View all 6 references
Moderate

Flucytosine (applies to flucytosine) hypokalemia

Moderate Potential Hazard, Moderate plausibility.

Flucytosine may cause hypokalemia. Patients with preexisting hypokalemia should be monitored closely for worsening electrolyte disturbances during therapy with flucytosine.

References

  1. Stamm AM, Diasio RB, Dismukes WE, et al. "Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis." Am J Med 83 (1987): 236-42
  2. "Product Information. Ancobon (flucytosine)." Roche Laboratories PROD (2002):

Flucytosine drug interactions

There are 97 drug interactions with flucytosine.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer